NCT02521389View on ClinicalTrials.gov

Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT-143

PHASE1CompletedINTERVENTIONAL

Enrollment

35

Participants

Timeline

Start Date

June 29, 2015

Primary Completion Date

February 24, 2017

Study Completion Date

February 24, 2017

Conditions

Malignancies

Interventions

DRUG

PWT-143

phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) delta inhibitor

Trial Locations (1)

NG11 6JS

Quotient Clinical, Ruddington

Sponsors

Lead Sponsor

MEI Pharma, Inc.

Collaborators (1)

Quotient Clinical

All Listed Sponsors

collaborator

Quotient Clinical

OTHER

lead

MEI Pharma, Inc.

INDUSTRY